posted
take a position here for a mid term plat at least.iIts in the Bio tech sector and priced right right now under .05. and with the new Avian flu issue on the rise this may be a good player. Hard as hell to buy though.
the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
HEADLINES Change Display [ hide $$ edit ] • CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues PR Newswire (Thu 5:00am) • CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of Stem Cell Collection and Storage Service PR Newswire (Wed 5:00am) • CALBATECH INC Financials EDGAR Online Financials (Tue, Sep 20) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Tue, Sep 13) • CalbaTech Announces Significant Six-Month Revenue Increase, Details the Company's Expectations for LifeStem Inc., Its Adult Stem Cell Subsidiary PR Newswire (Fri, Aug 12) • CalbaTech Announces Expansion At K-D Medical, Leading Manufacturer of Microbiological and Cell Culture Media, Allowing it to Significantly Grow the Business PR Newswire (Thu, Aug 11) • CalbaTech, Inc. Retains AGORACOM.Com to Expand Investor Awareness PR Newswire (Tue, Aug 2) • CALBATECH INC Files SEC form 8-K/A, Entry into Material Agreement, Financial Statements and Exhibits EDGAR Online (Tue, Jun 2 • CALBATECH INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online (Fri, Jun 3) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Mon, May 23)
posted
You missed the play on it yesterday. It showed up on one of dardadogs morning runners after it gapped. Matt
Posts: 1504 | Registered: Sep 2004
| IP: Logged |
posted
GREAT bio play under .05 so far,look at the chart history,this is a all time low pretty much and watching the news on the Avian flu I think many bio's are getting jiggy soon.The Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
About CalbaTech
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board, that intend to contribute innovation in areas of biological discovery.
Contact: Paul Knopick (949) 707-5365 pknopick*eandecommunications.com
posted
With everything going on about stem cell research and the scare of the Avian flu, this definitely sounds interesting.
CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues PR Newswire - October 06, 2005 05:00
IRVINE, Calif., Oct 06, 2005 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced that Dr. Jason Van Tassel has provided three pieces of stem cell related intellectual property to CalbaTech's wholly owned subsidiary LifeStem, Inc. Earlier this week, LifeStem announced that it is finalizing plans to offer a stem cell collection and storage service in selected markets.
"We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. "All three pieces of intellectual property complement our efforts in the stem cell arena and we're focused on developing them through our stem cell subsidiary LifeStem," Mr. DeOlden added.
The three pieces of intellectual property contributed by Dr. Van Tassel are related to therapeutic uses of autologous adult stem cells, and range from intellectual property related to the banking of stem cells to regeneration of tissue through the use of stem cells. The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office.
Dr. Van Tassel previously developed a novel method of injecting stem cells into diseased tissue through the use of a modified endoscope for which the company has filed for patent protection.
About CalbaTech
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing early stage life science based companies that are developing next generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute breakthrough innovation in areas of biological discovery.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc.
-------------------- "As long as there are dreamers, there are dreams that will come true." Posts: 862 | From: CT Yankee..... in FLA | Registered: Aug 2005
| IP: Logged |
posted
I still feel the same way about this as I did when I posted it yesterday...guess the thread got buried.
Posts: 688 | Registered: Aug 2005
| IP: Logged |
THE STEM-CELL LEGISLATION that has sparked controversy in Washington and rekindled the debate about when life begins also presents a puzzle to investors. Put your money in a company that could benefit from additional federal funding, and you run the risk of President Bush fulfilling his promise to veto any bill that would finance the related research. But sit this one out, and the legislation could eventually push through in one form or another, allowing public companies that conduct such research to capitalize on the government's deep coffers. What's a biotech investor to do? The answer may be to toe the line between the controversial and the ground-breaking. By investing in companies that conduct stem-cell research not involving contentious embryonic stem cells, investors can hedge their bets, taking advantage of the added attention to the field while relying on a more conventional capital model: One that doesn't depend on the president's signature.
Aastrom Biosciences (ASTM) is such a company. It's conducting adult stem-cell research that doesn't require the destruction of the human embryo, thus insulating itself from the debates over which research deserves federal funding. Perhaps more importantly to investors, the 14-year-old company has begun to make progress on commercial products and has successfully treated patients with at least one of them in midstage clinical trials. Although these aren't the miracle cures for paralysis or Alzheimer's disease that many expected stem-cell research to deliver — most scientists agree treatments for those conditions will require embryonic stem cells — Aastrom has come up with some promising solutions for lesser maladies such as bone fractures and vascular damage.
With no drugs on the market yet — and approvals from the Food and Drug Administration still likely years away — revenues remain scarce. For its fiscal third quarter ended March 31, Aastrom pulled in just $252,000 from grants and sales of therapy kits to other researchers. The company's loss for the period added up to $3.3 million, or three cents a share. At quarter's end the company was sitting on $35.4 million in cash and short-term investments.
SmartMoney.com sat down with Aastrom Chief Executive Doug Armstrong to discuss how the company got started, what its products may soon do for patients, how its fundamentals measure up to its peers', and what in blazes its name means. Here's what he had to say.
SmartMoney.com: How did the company get started and become involved in stem-cell research?
Doug Armstrong: A team at the University of Michigan had developed an approach to be able to take a small amount of human tissue, particularly human bone marrow, and to culture it outside of the body so that it would grow in a normal way. And as part of that process, the stem cells that are found in bone marrow would replicate and grow as well. And that was pretty unique because there were a host of companies, even in the early '90s, that were trying to figure out how to grow stem cells found in the body, and there were a variety of approaches taken. Out of all of those companies in the '90s... we're the only ones with our doors open. They all shut down. And that was, I believe, fundamentally because the approach that was in that founding technology worked. In other words, it actually allowed us to grow these normal human cells and produce them in a way that they retained their functionality as tissue-forming cells, so that when you put them back into patients, they would function. They would form tissue. In all the other approaches that were employed where cells were put back into patients, they didn't grow tissues.
That's an interesting perspective which serves to illustrate a couple things. One is, it's not easy to grow these normal cells and have them retain their functionality when you want to use them for a therapeutic reason. And secondly, it's why stem cells from bone marrow got such a bad name — because there were all of these failures in trying to be able to access them, grow them and then utilize them clinically.
SM: Where do you get the stem cells that you use for patient treatments?
DA: They all come from the patient. Now, they could be regulated by the FDA and by EMEA in Europe as drug. They're biologics — biologic drugs — so they will have approvals. They will have labeling. They will have reimbursement codes — all of those things identical to drugs. There's one big difference, and that's the manufacturing, and this has been a real barrier to entry for many groups. It comes down to this: Usually if you're going to treat 100,000 patients with a drug, one lot of drug is manufactured and put in 100,000 vials and shipped out. In our case, we have 100,000 manufacturing runs, not one, because every manufacturing run is patient-specific.
We have worked hard to have a fully automated manufacturing process. And with that automation, we've built into modularity, so that we can go anywhere in the world right now and do pilot manufacturing locations for trials. Then, as we go into larger trials, and then into commercialization, manufacturing will actually be brought back into centralized manufacturing facilities, where we'll have the same platform automation technology.
So, the process works where the physician would write a prescription for cells. When the patient is going around for the blood test and the urine test and things like that, a small amount of marrow would be aspirated in an outpatient procedure [and] dropped in a shipping container that goes right to the manufacturing facility. The manufacturing facility provides it back to the hospital pharmacy, and it's available at that hospital when it needs to be used by the patient.
Part of the difficulty in seeing the vision is that there are certain things that aren't done today that will be done when this becomes a product. It's just like the central labs for pulling blood. In the old days, each physician did it. Now, they just go to a lab. That would just be part of our business — either integrating one of those labs or clinics, or we would hope to work with hospitals to help expand that need. So, there are certain things that are new here. You can't just plug-and-play.
SM: How long does that process take?
DA: It's a 12-day process. We have over the years worked it out so that it is the same process for every patient, and we have worked out the procedure so that every patient will have the product. That's been another big, big hurdle in our field, is how do you productize these cells? It's one thing to show that you have cells that can in a laboratory do this or that or have the capability to perform in a certain way. It's a whole other thing to turn that into a standard medical product that's going to be used for patients all over the world. And that's been a very difficult hurdle to clear for many groups, and it was for us early on, but we've had a number of years to be able to work that out. And part of that hurdle is that if it's going to be like a drug — in other words, a physician can write a prescription for it and the patient's going to get a reliable treatment — that drug's got to be there every time they write the prescription. So, that means the manufacturing process for the cells has to be very reliable. The cells that come out of that manufacturing process have to be very reliable in their numbers, in their function. It's no good if you get a million cells for one patient and a billion cells for another patient.
SM: So what's your estimate for an annual patient population for the bone-fracture treatment?
DA: For the fractures, we think the segment that's available to us is about 175,000 to 250,000. The number of fractures, of course, is much higher than that. This is the area of severe fractures that would be candidates for our indication. And the market for spine applications is approximately 400,000.
SM: And vasculature? DA: The patients in the United States that go to amputation are in the 200,000 to 250,000 range. The patients who are at the stage of getting these interventional procedures to hopefully stem that tide are more in the 500,000 range. And then you go to European and Japanese markets — that's a big, big market, and there is no effective therapeutic there...
There's been a series of clinical trials that have come out that show that if you take about a quart of bone marrow, concentrate it and inject it into that tissue, it can stimulate and regenerate that vascular tissue. And the link for us is that we've been able to show that we can effectively substitute for large volumes of bone marrow. So, that's partially the drive to be able to move into this indication.
SM: So, it seems as if embryonic stem cells would have no particular place in your business model.
DA: Yeah, our focus is on products and being in the clinic and starting to generate revenue. And we have our hands full with what we have in-house. We are very interested in what's happening in that area, of course, particularly with any research that begins to provide what's called effective instruction to the cells that can be a benefit to a tissue. As I was mentioning earlier, there are certain tissues that aren't normally replaced everyday in our bodies, like nerves. So, there needs to be some additional biology, I think, to help effectively solve that problem. And if some of that additional biology can be identified through the embryonic stem-cell work, we would immediately apply that to our own stem cells.
With bone marrow stem cells, there's a big difference here, in that you can't isolate, purify and put bone marrow stem cells in front of you. There are too few. No one's been able to do that. Our Tissue Repair Cells — they're not pure stem cells — are a real mixture of cells. If you destroy the integrity of that, you can't grow the stem cells anymore. Embryonic stem cells are different. They're pure. If you want to do research as a biologist, that's just what you need. They're all right there. They're pure. They're all the same. You can actually do research that you can't do with bone marrow stem cells. But it doesn't mean that some of the things you learn can't be applicable. So, we're very interested in seeing what is learned, so we can then apply it to our cells.
But do we see anything going into the clinics soon there? No. I think you're going to hear and will see the anecdotal amazing story come out, which is going to be good. But even from that point, getting to something that's going to be productized is going to take a while.
SM: Where did the company get its name?
DA: The company, Aastrom, is in Ann Arbor, Mich. The A-A is for Ann Arbor; the S-T-R-O-M is for stromal cell. It's a key part of the early and current technology. The company began operations in 1991. We'll call it an old-style biotech spinoff out of the University of Michigan with venture-capital backing and a pretty traditional format. The lead investors at that time actually brought me to lead the company, so I've been with the company since 1991, a pretty long stint. A very long stint. It was supposed to be two years. It didn't work out that way.
SM: There's been a lot of press recently about Big Pharma absorbing or collaborating with smaller-cap biotechs to augment their thinning pipelines. Is Aastrom is a good candidate for that kind of relationship?
DA: Pharma has not been active in the cell-therapy area because that's not what they do. That stated, they also haven't been engaged because of a lot of the failures that have occurred with cells over the past 10 years. They are waiting for, I think, unequivocal clinical results to show that these results work and a business model to show that they can make money. Those are our objectives. With that, we think partnering will begin to unfold in a more positive way. Part of our business model is to pursue at least marketing partners for the different indications of use.
SM: What about the reverse relationship, taking a smaller company on? DA: We have such a long list of applications ourselves, we probably would not be looking for someone who has a new application. What we might be looking for is someone that adds either critical mass or a related application in the marketplace, someone that could be otherwise supportive or synergistic with what we're doing. If our market cap continues to grow, we will put that capital to work and look to bring in additional components that would allow us to the either get to market sooner or in a larger way.
SM: Thomson First Call projects negative earnings per share for Aastrom into 2006. Can you account for those numbers, or do they concern you?
DA: Yes, and I think it's fine. We'll be investing in our clinical activities and research activities for a few years. Investors should look for value in the company, not from our revenues, but from definable clinical results from our clinical trials. Even though we're only spending money and raising money, we've shown steady growth in our market cap and in our share price, and we will continue that model for the next couple years. In May of 2003, we had a market cap of $24 million and share price of approximately 40 cents. So, this year, at the end of May, our share price was over $2.20, and our market cap was over $225 million.
SM: Why else should someone invest in Aastrom?
DA: I think it comes down to a couple of pretty important, basic things. One is this is a company that's not focused on cool technology. It's focused on cool products. The products are now in the clinic in trials. There should be a continuous flow of clinical milestones coming out of this company from now until we get into revenues. And, talking about tissue regeneration, you either grow tissue or you don't. So, you're not running a 200,000-patient trial to get a statistic like a 10% difference in five-year survivals. We're really looking at pretty definitive, early-term types of indicators to show that things are working.
News flow will be pretty continuous out of these clinical pathways. So, there should be, we think, the opportunity to value growth in measurable ways. You're also going to be able to begin to track, with each month that goes by as we work through this process, the real timeline until revenues will be there, where they're going to come from and how that's going to work out. The business model will begin to firm up with announceable events. One of our milestones for the next six months is to establish our first pilot commercial manufacturing facility in Europe.
So, we've already mitigated a lot of the technology risk for the investor. The cells are safe when we put them in patients. We know that they can generate healthy, normal tissue. We know that they're functional. So, it really comes down to what's the specific indication, the product, and when do we get to revenue. And that's what you can begin to track with this company. In the space, there's no one else close to being able to have that type of story
posted
just got back in,seems I missed 2 calls from the southwest...LOL....yeah Texas...I'll let ya'll kow what is said if I can reach them back!!
Did anyone try to buy CLBE? I only got several partials up to .049, see how hard buying low floaters are! they move quick though once they start.I contacted a friend to let him in on this but he already took a position yesterday,figured I would return the favor since he turned me on to BIPH at .09,I tried giving him AMEP at .013's but he only plays the Biotechs!!! I told his butt to step out of the box for once...I know he regrets it now I bet!
posted
all the good pennies require patience and some stocks are just right in your face screaming STRONG BUY like this one,hell all the financials are in order and their business plan is excellent from everything I have read so far and look at the filings,simply flawless...this alone tells me they mean REAL business and also in a great sector second only to energy. Logged
posted
Here's my email response from Joe Christopher re: Berlin Exchange Cathy:
We have had several investors inquire this morning about the impact the Berlin exchange has had on our stock. We have requested in the past to be de-listed on that exchange. They have not responded. In reality there is not really much that we can do.
The real question is how much trading is taking place on the Berlin exchange? This morning when we had traded over 14 million shares only 116 thousand had traded on that exchange.
I believe the real problem lies with our own stockholders who bought recently in the quick run up. They didn’t have a real understand on the company. They were only buying because a computer program drew their attention to it due to price movement, volume and momentum. They are now selling for the same reason. The heard mentality is rarely right.
My advice, as always, is to put your AMEP stock into a nice clean envelope and slip it between your mattresses.
Take it out in a year and I believe you will be pleasantly surprised.
If you have any questions please call me at (800) 417-3670 Joe Christopher
Posts: 26 | Registered: Sep 2005
| IP: Logged |
Did anyone try to buy CLBE? I only got several partials up to .049, see how hard buying low floaters are! they move quick though once they start.I contacted a friend to let him in on this but he already took a position yesterday,figured I would return the favor since he turned me on to BIPH at .09,I tried giving him AMEP at .013's but he only plays the Biotechs!!! I told his butt to step out of the box for once...I know he regrets it now I bet!
Yes, I'm in too. I'm averaged at .044, so hopefully this keeps on going!
-------------------- "As long as there are dreamers, there are dreams that will come true." Posts: 862 | From: CT Yankee..... in FLA | Registered: Aug 2005
| IP: Logged |
posted
At this point, Quest, I'm not sure which one has more national attention. I THOUGHT it was oil and natural gas, but with the attention that this Avian Flu is getting, and what it could do if it spread here, is way beyond what I want to think about. I see in the AMEP thread where Bmax said to be careful. I plan to be. I used to have ASTM when it was under 1.00.. LOL, and sold it because I thought it was garbage. I am NOT making that mistake again. Stem research isn't going away.
-------------------- "As long as there are dreamers, there are dreams that will come true." Posts: 862 | From: CT Yankee..... in FLA | Registered: Aug 2005
| IP: Logged |
posted
Quest: I got a few hundred dollars in CLBE this afternoon. Reading the 10K right now. I'll let you know my thoughts later.
Does your bio-tech friend know anything about Hana Bioscience (HBX)? I got into it a few weeks ago. They have a few products in the pipeline. Really low volume, a fair amount of institutional holding, and the price moves very easily. Analyst valued the company at between $8 and $12 a share, they're currently trading around $4. Just wondering if you or anyone else has any thoughts.
Posts: 133 | From: Blacksburg, VA | Registered: Sep 2005
| IP: Logged |
posted
mmalone...I will ask him in an e-mail but he may not return an answer until afternoon tomorrow.
SuperBee....Stem cell research is not going away at all imo,they have already been looking for back doors around the issue.CLBE is into more then that though,they are postionaing themselves to cover a wide spectrum in the Biotech sectors,way under valued imo and with such a ridiculus low float and OS its no wonder why even a 15k buy will bump up the B/A so quick.
posted
I posted today that the RSI was very bearish for CLBE but all these indicators are setting up for a reversal.Do you remember way back then when I first started posting AMEP? I clearly stated on this board and others that I try to enter when everyone wants out and it looks to be on the declince (as long as I know its a good company),I post to everyone when I feel a good entry is set and its time to get in early which is now for CLBE.Maybe CLBE is not your choice but seriously watch for the Avion (bird)Flu stocks to really wake up,this epidemic could easily kill 100's of millions per Fox news.Many Biotechs I believe will be looking into the flu issue especially those like CLBE that has a wide spectrum other then stem cell research.I see a thread was started specifically for the Avian Flu...thats a great idea,not only does it give us many good ideas for investment but in the DD process many will get educated on just how bad this Flu can be!
posted
kywee.....I have no doubt that there will be Americans killed due to this,we are not indistructable and with the way people travel hell anyone sick could just hang out at an airport and infect many people going all over the country or world....its some scary CHIT to say the least!
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
MoleculareWare helps scientists have the wherewithal to keep their As, Cs, Gs, and Ts straight. The firm, a subsidiary of CalbaTech, offers bioinformatics software and other products to integrate the volumes of data produced from high throughput screening, combinatorial synthesis, and other methods of genomics research. Its DigitalGENOME suite consists of three software programs. DesignerDG can configure microplates and track the liquids used in the microplate wells. AnalyzerDG analyzes images and manages data from microarrays; the software can be used as part of DigitalGENOME or on its own. IntegratorDG can integrate data stored in a variety of database platforms, including platforms from Oracle and Microsoft.
Drug Week, 09/15/2005 07:18:31 PM EDT) CalbaTech, Inc., announced that revenues for the 6 months ended June 30, 2005, totaled $625,345, up from $58,217 for the same period in 2004. Revenues for the second quarter totaled $310,525, compared to revenues of $40,941 for the same period in 2004.
(Biotech Week, 09/15/2005 07:08:23 PM EDT)
(Medical Devices & Surgical Technology Week)
Biotech Week
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
posted
CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues
CalbaTech, Inc., an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced that Dr. Jason Van Tassel has provided three pieces of stem cell related intellectual property to CalbaTech's wholly owned subsidiary LifeStem, Inc. Earlier this week, LifeStem announced that it is finalizing plans to offer a stem cell collection and storage service in selected markets.
"We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. "All three pieces of intellectual property complement our efforts in the stem cell arena and we're focused on developing them through our stem cell subsidiary LifeStem," Mr. DeOlden added.
The three pieces of intellectual property contributed by Dr. Van Tassel are related to therapeutic uses of autologous adult stem cells, and range from intellectual property related to the banking of stem cells to regeneration of tissue through the use of stem cells. The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office.
Dr. Van Tassel previously developed a novel method of injecting stem cells into diseased tissue through the use of a modified endoscope for which the company has filed for patent protection.
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets.
The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services.
"LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection.
LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells.
posted
CLBE--filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
this is good because all the controversy over harvesting stem cells from embryos may be over,CLBE has found a way to harvest from adults,this is just one thing they are involved in,look for PR's soon imo on the others.
posted
CalbaTech is focused on providing products and platforms to the life sciences research market, both for biotech and pharmaceutical companies, as well as academic and government institutions. CalbaTech is pursuing a classic "roll-up" strategy of growth by acquisition. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that CalbaTech believes will contribute breakthrough innovation in areas of biological discovery. Currently, CalbaTech contains four wholly owned subsidiaries, Molecula Research Laboratories, LLC. ("Molecula"), KD Medical, Inc. ("KD"), LifeStem, Inc. ("LifeStem") and Molecularware, Inc. ("Molecularware") that serve niche markets in the life sciences research market. Molecula and Molecularware were acquired by CTI in 2003, KD was acquired in November 2004, and LifeStem was incorporated in September 2004 to pursue opportunities in the rapidly expanding stem cell market.
In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
CTI's business strategy is establish shareholder value by creating a significant new provider of research reagents, equipment and services to the life sciences market, primarily through acquisition of life science companies that share two or more of the following attributes: 1) They will be generating revenues; 2)They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
as for this one CLBE...the more I was digging the last few days the better it looked for a mid to long term investment,if they announce the patent approval for stem cell recovery from adults this will go crazy especially since all the controversy over embryonic cells is not going away easy!CLBE has a wide spectrum of R&D going on and not just stem cell research,one of these Bio's are going to nail the golden goose with an Avian flu vaccine you watch!!
CalbaTech is focused on providing products and platforms to the life sciences research market, both for biotech and pharmaceutical companies, as well as academic and government institutions. CalbaTech is pursuing a classic "roll-up" strategy of growth by acquisition. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that CalbaTech believes will contribute breakthrough innovation in areas of biological discovery. Currently, CalbaTech contains four wholly owned subsidiaries, Molecula Research Laboratories, LLC. ("Molecula"), KD Medical, Inc. ("KD"), LifeStem, Inc. ("LifeStem") and Molecularware, Inc. ("Molecularware") that serve niche markets in the life sciences research market. Molecula and Molecularware were acquired by CTI in 2003, KD was acquired in November 2004, and LifeStem was incorporated in September 2004 to pursue opportunities in the rapidly expanding stem cell market.
In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
CTI's business strategy is establish shareholder value by creating a significant new provider of research reagents, equipment and services to the life sciences market, primarily through acquisition of life science companies that share two or more of the following attributes: 1) They will be generating revenues; 2)They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
been looking at the chart for this lil puppy again this morning and still cannot believe I missed this one so long,this one should carry an average of .175 PPS with a few high spikes based on normal operations alone.
2 in the .07's and all the rest are .12 and above!!
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets.
The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services.
"LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection.
LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
